



PRIOR AUTHORIZATION POLICY

- POLICY:** Oncology – Nilutamide Prior Authorization Policy
- Nilandron[®] (nilutamide tablets – Concordia, generic)

REVIEW DATE: 01/17/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Nilutamide, in combination with surgical castration, is indicated for the treatment of **metastatic prostate cancer (Stage D₂)**.¹ For maximum benefit, nilutamide treatment must begin on the same day as or on the day after surgical castration.

Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines for **prostate cancer** (version 4.2023 – September 7, 2023) recommend nilutamide in combination with luteinizing hormone-releasing hormone agonists [Lupron[®] (leuprolide subcutaneous injection), Lupron Depot[®] (leuprolide acetate intramuscular injection), Trelstar[®] (triptorelin pamoate intramuscular injection), Zoladex[®] (goserelin acetate subcutaneous implant), Vantas[®] (histrelin acetate subcutaneous implant)] with or without external beam radiation therapy for androgen deprivation therapy.^{2,3}

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of nilutamide. All approvals are provided for the duration noted below.

- **Nilandron® (nilutamide tablets (Concordia, generic)**

is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

- 1. Prostate Cancer.** Approve for 1 year if nilutamide is used concurrently with a luteinizing hormone-releasing hormone (LHRH) agonist.
Note: Examples are Lupron (leuprolide subcutaneous injection), Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant).

CONDITIONS NOT COVERED

- **Nilandron® (nilutamide tablets (Concordia, generic)**

is(are) considered experimental, investigational or unproven for ANY other use(s).

REFERENCES

1. Nilandron® [prescribing information]. St. Michael, Barbados: Concordia; May 2017.
2. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 4.2023 – September 7, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed January 10, 2024.
3. The NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed January 10, 2024. Search term: nilutamide.

HISTORY

| Type of Revision | Summary of Changes | Review Date |
|-------------------------|---------------------------|--------------------|
| Annual Revision | No criteria changes. | 01/18/2023 |
| Annual Revision | No criteria changes. | 01/17/2024 |

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.